Terns Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Terns Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage oncology company with potentially best-in-disease CML therapy showing strong Phase 1 data, well-funded through 2028, advancing toward pivotal trials in 2026. The company raised $747.5 million in a December 2025 capital offering, with expected cash runway into 2028. Multiple key milestones planned for 2026 include pivotal dose selection.
What is Terns Pharmaceuticals, Inc.'s industry? Terns Pharmaceuticals, Inc. (ternspharma.com) operates in Biopharmaceutical/Clinical-Stage Oncology. AskCyborg classifies Terns Pharmaceuticals, Inc. under Biopharmaceutical/Clinical-Stage Oncology in its company registry.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology and obesity. The company completed its transition to an oncology compan...
Cyborg Score thesis
Clinical-stage oncology company with potentially best-in-disease CML therapy showing strong Phase 1 data, well-funded through...
Read the full analyst-debate transcript →Get the Latest Terns Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTerns Pharmaceuticals, Inc. Overview
Pro stress-test →Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology and obesity. The company completed its transition to an oncology company anchored by TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML).
Strategic Profile
Pro stress-test →TERN-701 is a highly selective allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing CML treatments. The Phase 1 CARDINAL trial showed a 75% cumulative major molecular response (MMR) rate by 24 weeks with 100% MMR durability and encouraging safety across doses.
Competitive Landscape
Pro stress-test →TERN-701 is positioned against second-generation TKI competitors including dasatinib, nilotinib, and bosutinib in planned pivotal trials. The allosteric mechanism and enhanced safety profile offer potential differentiation in the CML treatment space. Multiple phase-appropriate clinical candidates are in development at competing biotech and established pharmaceutical companies.
Industry Context
Terns Pharmaceuticals, Inc. operates in Biopharmaceutical/Clinical-Stage Oncology.
Key facts
Founded: 2015 · Headquarters: Foster City, United States · Market cap: $3.4B